Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 5;18(1):2550370.
doi: 10.1080/20523211.2025.2550370. eCollection 2025.

Stakeholder engagement and pharmaceutical pricing regulation: a qualitative inquiry

Ye Shing Lourdes Loh  1 , Sharon G M Koh  1 , Audrey K L Siah  1 , Wing Loong Cheong  2 , Tin Tin Su  3
Affiliations

Stakeholder engagement and pharmaceutical pricing regulation: a qualitative inquiry

Ye Shing Lourdes Loh et al. J Pharm Policy Pract. .

Abstract

Background: Medicine affordability is a critical component of a country's redistributive health policies aimed at ensuring equitable access to healthcare. This study aims to investigate key stakeholders' perspectives on pharmaceutical pricing control in Malaysia as the country is moving towards sustainable healthcare.

Methods: Semi-structured interviews (n = 16) were conducted with a purposive sampling of key stakeholders, which included practitioners and policymakers engaged in Malaysia's public health policy. Data were analysed using thematic analysis guided by Walt and Gilson's [(1994). Reforming the health sector in developing countries: The central role of policy analysis. Health Policy and Planning, 9(4), 353-370. https://doi.org/10.1093/heapol/9.4.353] Health Policy Triangle framework.

Results: The findings indicate a range of opinions among stakeholders, with most generally favouring the implementation of pharmaceutical pricing regulation. However, concerns have been raised about potential cost transfer, where medication expenses may be shifted to other medical services. Furthermore, there are apprehensions that price controls could adversely affect the profitability of the pharmaceutical industry and impede the development of innovative drugs. Proposed measures include the introduction of price controls and the enhancement of price transparency for specific medications used to address acute and major health issues.

Conclusion: Our study contributes to the current understanding of the formation of public health policies to improve social welfare through stakeholder engagement to ensure that it reflects public needs. Malaysia is a valuable example for developing countries seeking equitable access to manage rising healthcare costs. The study is crucial for understanding country-specific experiences and stakeholders' views on pharmaceutical pricing regulations.

Keywords: Public health; external reference pricing; pharmaceutical pricing policy.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Key elements of the health policy triangle framework. Source: Author’s own illustration adapted from Walt and Gilson (1994).
See this image and copyright information in PMC

References

    1. Acosta, A., Vanegas, E. P., Rovira, J., Godman, B., & Bochenek, T. (2019). Medicine shortages: Gaps between countries and global perspectives. Frontiers in Pharmacology, 10, 763. 10.3389/fphar.2019.00763 - DOI - PMC - PubMed
    1. Ahmad, N. S., Hatah, E., & Makmor-Bakry, M. (2019). Association between medicine price declaration by pharmaceutical industries and retail prices in Malaysia's private healthcare sector. Journal of Pharmaceutical Policy and Practice, 12(1), 15. 10.1186/s40545-019-0176-z - DOI - PMC - PubMed
    1. Ahmad, N. S., Makmor-Bakry, M., & Hatah, E.. (2020). Multi-stakeholder perspectives on medicine price transparency initiatives in private healthcare settings in Malaysia. Saudi Pharmaceutical Journal, 28(7), 850–858. 10.1016/j.jsps.2020.05.016 - DOI - PMC - PubMed
    1. Ashraf, A., & Ong, S. C. (2021). A case for external reference pricing to regulate drug costs in low- and middle-income countries. British Journal of Healthcare Management, 27(10), 1–4. 10.12968/bjhc.2021.0050 - DOI
    1. Babar, Z.-U.-D. (2022). Forming a medicines pricing policy for low and middle-income countries (LMICs): The case for Pakistan. Journal of Pharmaceutical Policy and Practice, 15(1), 9–15. 10.1186/s40545-022-00413-3 - DOI - PMC - PubMed

LinkOut - more resources